The Expressions of NF−κB, COX−2, Sp1, and c−Jun in Pancreatic Ductal Adenocarcinoma and Their Associations with Patient Survival
Authors:
- Kaka RenaldiKaka Renaldi
- Marcellus SimadibrataMarcellus Simadibrata
- Nur RahadianiNur Rahadiani
- Diah Rini HandjariDiah Rini Handjari
- Alida Roswita HarahapAlida Roswita Harahap
- Kuntjoro HarimurtiKuntjoro Harimurti
- Nasrul ZubirNasrul Zubir
- Lianda SiregarLianda Siregar
- Imelda Maria LohoImelda Maria Loho
- Evlina SuzannaEvlina Suzanna
- Bonita PrawirodihardjoBonita Prawirodihardjo
- Heriawaty HidajatHeriawaty Hidajat
Open Access
- 25 March 2023
- journal article
- research article
- Published by MDPI AG in Pathophysiology
- Vol. 30 (2) , 92-109
Abstract
Chronic inflammation is a crucial driver of carcinogenesis in pancreatic ductal adenocarcinoma (PDAC). Several studies have investigated the prognostic significance of cyclooxygenase−2 (COX−2) expression in PDAC patients, obtaining conflicting results. Nuclear factor kappa−B (NF−κB), specificity protein 1 (Sp1), and c−Jun are known as the transcription factors of the COX2 gene. This exploratory observational study investigated the association of the NF−κB, COX−2, Sp1, and c−Jun expressions with patient survival in PDAC. We used the immunohistochemical method to detect the PDAC tissue expressions of NF−κB (RelA/p65), COX−2, Sp1, and c−Jun. The expressions of these proteins were correlated with the overall survival (OS) and other clinicopathological characteristics of PDAC patients. We obtained 53 PDAC specimens from resections and biopsies. There were significant correlations between the four proteins’ expressions in the PDAC tissues. The expression of the cytoplasmic (aHR = 0.31; 95% CI 0.11–0.90; p = 0.032) or nuclear NF−κB (aHR = 0.22; 95% CI 0.07–0.66; p = 0.007) was independently associated with a better prognosis in the PDAC patients. COX−2, Sp1, and c−Jun showed no significant association with a prognosis in the PDAC patients. The PDAC patients who expressed NF−κB had a better prognosis than the other patients, which suggests that the role of inflammation in PDAC is more complex than previously thought.Keywords
Funding Information
- Directorate of Research and Development, Universitas Indonesia, under Hibah PUTI 2022 (NKB−1589/UN2.RST/HKP.05.00/2020)
This publication has 49 references indexed in Scilit:
- Cell Intrinsic Role of COX-2 in Pancreatic Cancer DevelopmentMolecular Cancer Therapeutics, 2012
- Myeloid, but Not Pancreatic, RelA/p65 Is Required for Fibrosis in a Mouse Model of Chronic PancreatitisGastroenterology, 2011
- Involvement of COX-2/PGE2Pathway in the Upregulation of MMP-9 Expression in Pancreatic CancerGastroenterology Research and Practice, 2011
- Cyclooxygenase-Deficient Pancreatic Cancer Cells Use Exogenous Sources of ProstaglandinsMolecular Cancer Research, 2010
- Overexpression of Sp1 leads to p53‐dependent apoptosis in cancer cellsInternational Journal of Cancer, 2009
- High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosisBritish Journal of Cancer, 2007
- Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradationProgress in Lipid Research, 2007
- Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancerJournal of Clinical Pathology, 2006
- Good cop, bad cop: the different faces of NF-κBCell Death & Differentiation, 2006
- NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasiaNature, 2003